Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

@article{Mehta2011EffectiveTO,
  title={Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90},
  author={P. Mehta and P. Whalen and S. Baxi and P. Kung and S. Yamazaki and M. Yin},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={5432 - 5442}
}
Purpose: Triple-negative breast cancer (TNBC) patients have poor prognoses and survival outcomes such that the development of new targeted therapies is in strong demand. Mechanisms associated with high proliferation and aggressive tumor progression, such as PI3K/PTEN aberration, epidermal growth factor receptor (EGFR) overexpression, and cell-cycle upregulation, play important roles in TNBC. The molecular chaperone Hsp90 is required for the conformational maturation and stability of a variety… Expand
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer
TLDR
It is suggested that GR-regulated anti-apoptotic and pro-proliferative signaling networks in TNBC are disrupted by Hsp90 inhibitors, thereby sensitizing TNBC to paclitaxel-induced cell death. Expand
Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
TLDR
The preclinical activity profile and clinical evidence of tumor regression suggest that ganetespib offers considerable promise as a new therapeutic candidate to target TNBC. Expand
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
TLDR
In contrast to 17-allylamino-17-demethoxygeldanamycin (17-AAG), PF4942847 did not induce osteoclast differentiation, and synergistically acted with zoledronic acid to delay osteosarcoma progression and prevent bone lesions. Expand
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
TLDR
Ganetespib treatment markedly impaired primary tumor growth and vascularization, and eliminated local tissue invasion and distant metastasis to regional lymph nodes and lungs, thereby providing a molecular basis for observed effects of the drug on the growth and metastasis of triple-negative breast cancer. Expand
Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer
TLDR
The antitumor activity of panepoxydone (PP), a NF-κB inhibitor isolated from an edible mushroom, is reported for the first time in several breast cancer cell lines, suggesting that the PP may be a potentially effective chemopreventive or therapeutic agent against breast cancer. Expand
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
TLDR
Ganetespib potently inhibits Hsp90 leading to the degradation of multiple clinically-validated oncogenic client proteins in breast cancer cells, encompassing the broad spectrum of molecularly-defined subtypes. Expand
Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
TLDR
The results of Hsp90 inhibitors in combination with trastuzumab and other cancer drugs are discussed and recent results from yeast focused on the genetics of drug resistance when HSp90 is inhibited are discussed. Expand
17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
TLDR
17-DMCHAG is a highly effective and low-hepatotoxic geldanamycin derivative that exhibits antitumor activity against human prostate cancer cells and is a potential treatment for prostate cancer. Expand
Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
TLDR
The results suggest that CH5164840 was more efficacious in HER2-positive tumors than in Her2-negative tumors in terms of the lower effective concentration of the drug in preclinical animal models. Expand
Targeting triple negative breast cancer: is p53 the answer?
TLDR
Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 42 REFERENCES
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
TLDR
The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp 90 inhibitor PU-H71 for clinical trials involving patients with TNBC. Expand
Hsp90: an emerging target for breast cancer therapy
TLDR
Several small molecule inhibitors of Hsp90 have been identified that can deplete cellular levels of multiple oncogenic client proteins simultaneously by enhancing their ubiquitination and proteasome-mediated degradation. Expand
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
TLDR
Based on its ability to deplete the ER as well as other critical signaling molecules in Tam-resistant breast cancer, 17AAG may provide a useful alternative treatment for patients with recurrent, hormone-refractory breast cancer that should be explored further in Phase II trials. Expand
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
TLDR
This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors and has significant anticancer activity in patients with HER2-positive, metastatic breast cancer previously progressing on trastuzumab. Expand
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
TLDR
STA-9090, at low nanomolar concentrations, potently arrested cell proliferation and induced apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Expand
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
TLDR
NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings and recently has entered clinical phase I breast cancer trials. Expand
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers
TLDR
Hsp90 inhibition with SNX-2112 (delivered as a prodrug) may represent a promising therapeutic strategy for tumors whose growth and survival is dependent on Hsp90 clients. Expand
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
TLDR
Oral administration of BIIB021 led to the degradation of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models. Expand
PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality
TLDR
It is concluded that >70% of breast cancers have an alteration in at least 1 component of the PI3K pathway and this might be exploited to therapeutic advantage especially in “basal‐like” cancers. Expand
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
TLDR
The PI3K pathway was found to be activated in BLCs and up-regulated compared with HER2+ tumours as shown by a significantly increased activation of the downstream targets Akt and mTOR (mammalian target of rapamycin). Expand
...
1
2
3
4
5
...